Stalevo Drug Information
The U.S. Food and Drug Administration (FDA) has approved Stalevo® (carbidopa-levodopa-entacapone) for the treatment of Parkinson's disease. Specifically, this drug is approved for use in the following situations:
- As a replacement for carbidopa-levodopa in people experiencing "wearing-off" symptoms (when the medication stops working before the next dose) who take 600 mg of levodopa per day or less and who are not experiencing dyskinesia, a movement disorder that is a side effect of carbidopa-levodopa.
- As a substitute for carbidopa-levodopa (Sinemet®) tablets and entacapone (Comtan®) tablets in people already taking these medications.
The main component of Stalevo (levodopa) is used for treating symptoms of Parkinson's, while the other two components (carbidopa and entacapone) help levodopa work better and longer. Stalevo comes in the form of a tablet and is usually taken three or four times a day.
Although most people tolerate it well, Stalevo is not right for everyone. Safety information on this drug should be reviewed with your healthcare provider before beginning treatment. This includes knowing what products could cause drug interactions and being aware of possible side effects.
(For more information on this drug, click Stalevo. This article gives a complete overview, including how this product performed in clinical trials.)